Welcome!
I am an NIH/NIBIB-funded Principal Investigator at Harvard Medical School. My work focuses on designing and synthesizing radically engineered genomes with modified genetic codes to i.) achieve resistance to all natural viruses, ii.) biocontain organisms and their engineered genetic information, and iii.) produce genetically encoded polymers and biologic drugs beyond the limits of natural protein synthesis. Prior to Harvard, as a Boehringer Ingelheim Fonds Ph.D. Fellow, I developed synthetic biology tools for accelerated directed evolution and utilized these tools for rational drug design and development. Most recently, I received a K99/R00 Award from the US National Institute of Biomedical Imaging and Bioengineering, with which I am working on the clinical translation of these technologies.
More about my research & publications.
We merge multi-omics, genome design & genetic code engineering, and computational chemistry with protein engineering, drug development, and directed evolution to enable therapeutic and industrial applications that are not attainable with existing living organisms and biopolymers.
Intermolecular interactions of a nonstandard amino acid within an aminoacyl-tRNA synthetase enzyme. The rational engineering of these interactions paves the way for novel, genetically encoded biopolymers, protein and peptide drugs, and enables tight - potentially escape-free - biocontainment for living organisms and their engineered genetic information.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.